Advertisement

Hypercoagulative syndrome: Molecular markers for the identification of cardiovascular patients at risk

  • Hans Martin Hoffmeister
  • W. Heller
  • L. Seipel
Chapter
  • 84 Downloads

Summary

In many cardiovascular diseases thromb-embolic events play a key role. Especially in patients with acute coronary syndromes a hypercoagulative state is known. Information, however, whether such alterations do exist prior to the clinical event is limited. Recent progress in the development of sensitive and specific tests to determine molecular markers of (re)activation of several pathways of the coagulation and of the fibrinolytic system is evident. The possible impact of such molecular markers for the identification of cardiovascular patients at risk as well as the meaning of such markers to prognosticate future cardiovascular events is summarized.

Key words

Molecular markers coagulation fibrinolysis inflammation tissue injury 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Angleton P, Chandler WL, Schmer G (1989) Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 79:101–106PubMedCrossRefGoogle Scholar
  2. 2.
    Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E (1996) Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 335:1342–1349PubMedCrossRefGoogle Scholar
  3. 3.
    Ardissino D, Merlini PA, Gambo G, Barberis P, Demichelli G, Testa S, Colombi E, Poli A, Fetiveau R, Montemartini C (1996) Thrombin activity and early outcome in unstable angina pectoris. Circulation 93: 1634–1639PubMedGoogle Scholar
  4. 4.
    Cronlund M, Hardin J, Burton J, Lee L, Haber E, Bloch KJ (1979) Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus. J Clin Invest 58:142–151CrossRefGoogle Scholar
  5. 5.
    ECAT angina pectoris study group (1993) ECAT angina pectoris study: baseline associations of haemostatic factor with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Europ Heart J 14:8–17CrossRefGoogle Scholar
  6. 6.
    Gulba DC, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, Hecker H, Lichtlen PR (1991) Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation 83:937–944PubMedGoogle Scholar
  7. 7.
    Hamsten A, Walldius G, Szamosi A, Blombäck M, De Faire U, Dahlen G, Landou C, Wiman B (1987) Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3–9PubMedCrossRefGoogle Scholar
  8. 8.
    Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 349:462–466PubMedCrossRefGoogle Scholar
  9. 9.
    Hoffmeister HM, Jur M, Heller W, Seipel L (1995) Hyperkoagulabilität bei akutem koronaren Syndrom: Beeinflussung durch eine PTCA als Akutintervention. In: Heinle H, Schulte H, Kaffernik H: Arteriosklerose; W. Kohlhammer, Stuttgart, pp 141–145Google Scholar
  10. 10.
    Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L (1995) Alterations of the coagulation, the fibrinolytic and the kallikrein-kinin system in the acute and post-acute phase in patients with unstable angina pectoris. Circulation 91:2520–2527PubMedGoogle Scholar
  11. 11.
    Hoffmeister HM, Jur M, Heller W, Seipel L (1997) Korrelation zwischen molekularen Schädigungsmarkern und der Gerinnung bei Patienten mit instabiler Angina pectoris. Z Kardiol 86:68Google Scholar
  12. 12.
    Hursting MJ, Butman BT, Steiner JP et al. (1993) Monoclonal antibodies specific for prothrombin fragment 1,2 and their use in a quantitative enzyme-linked immunosorbent assay. Clin Chem 39:583–591PubMedGoogle Scholar
  13. 13.
    Katus HA, Loser S, Hallermayer K et al. (1992) Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin Chem 38:386–393PubMedGoogle Scholar
  14. 14.
    Marder VJ (1990) What does the“dimer test” test? Circulation 82:1514–1515PubMedCrossRefGoogle Scholar
  15. 15.
    Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61–68PubMedGoogle Scholar
  16. 16.
    Munkvad S, Gram J, Jespersen J (1990) A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 11:525–528PubMedGoogle Scholar
  17. 17.
    Nossel HL, Younger LR, Wilner GD, Procupez T, Canfield RE, Butler VP Jr (1971) Radioimmunoassay of human fibrinopeptide A. Proc Natl Acad Sci USA 68:2350–2353PubMedCrossRefGoogle Scholar
  18. 18.
    Nossel HL, Yudelman I, Canfield RE et al. (1974) Measurement of fibrinopeptide A in human blood. J Clin Invest 54:43–53PubMedCrossRefGoogle Scholar
  19. 19.
    Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler VP Jr (1976) The generation of fibrinopeptide A in clinical blood samples: Evidence for thrombin activity. J Clin Invest 58:1136–1144PubMedCrossRefGoogle Scholar
  20. 20.
    Ohman EM, Armstron PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O’Hanesian MA, Wagner GS, Kleiman NS, Harreil FE, Califf RM, Topol EJ (1996) Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 335:1333–1341PubMedCrossRefGoogle Scholar
  21. 21.
    Pelzer H, Schwart A, Stuber W (1991) Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemostas 65:153–159Google Scholar
  22. 22.
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 336:973–979PubMedCrossRefGoogle Scholar
  23. 23.
    Vaziri ND, Kennedy SC, Kennedy D, Gonzales E (1992) Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 93:651–657PubMedCrossRefGoogle Scholar
  24. 24.
    Wiman B, Hamsten A (1990) Correlations between fibrinolytic function and acute myocardial infarction. Am J Cardiol 66: 54G–56GPubMedCrossRefGoogle Scholar
  25. 25.
    Yasuda M, Takeuchi K, Hiruma M, Iida H, Tahara A, Itagane H, Toda I, Akioka K, Teragaki M, Oku H, Kanayama Y, Takeda T, Kolb WP, Tamerius JD (1990) The complement system in ischemic heart disease. Circulation 81:156–163PubMedCrossRefGoogle Scholar
  26. 26.
    Zalewski A, Shi Y, Nardone D, Bravette B, Weinstock P, Fischmann D, Wilson P, Goldberg S, Levin DC, Bjornsson TD (1991) Evidence for reduced fibrinolytic activity in unstable angina at rest. Circulation 83: 1685–1691PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 2000

Authors and Affiliations

  • Hans Martin Hoffmeister
    • 1
  • W. Heller
    • 1
  • L. Seipel
    • 1
  1. 1.Abteilung Innere Medizin IIIMedizinische UniversitätsklinikTübingenGermany

Personalised recommendations